157:, which is expressed on T cells and tends to down-regulate an immune response. In a June 2015 presentation Novartis management indicated that 'dosing is imminent' for the first clinical trials of LAG525.
164:(PDR001), an anti-PD-1 monoclonal antibody has been completed. Recruiting for a phase 2 study in combination with spartalizumab for the treatment of metastatic melanoma is underway.
229:
for "Study of
Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma (PLATforM)" at
42:
248:
181:
253:
211:
for "Safety and
Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies." at
90:
160:
Ieramilimab's first clinical trial is a Phase I in patients with various solid tumors, in combination with
139:
70:
35:
230:
212:
151:
79:
143:
99:
242:
161:
225:
207:
28:
147:
17:
119:
154:
110:
182:"Meet Novartis Management presentation, 17/18 June 2015"
150:
for the treatment of cancer. The antibody targets the
109:
89:
69:
64:
56:
51:
41:
34:
78:
8:
27:
98:
173:
26:
7:
118:
25:
1:
270:
249:Experimental cancer drugs
223:Clinical trial number
205:Clinical trial number
254:Monoclonal antibodies
140:monoclonal antibody
36:Monoclonal antibody
31:
231:ClinicalTrials.gov
213:ClinicalTrials.gov
134:(development code
152:immune checkpoint
129:
128:
16:(Redirected from
261:
233:
221:
215:
203:
197:
196:
194:
192:
186:
178:
122:
102:
82:
32:
30:
21:
269:
268:
264:
263:
262:
260:
259:
258:
239:
238:
237:
236:
222:
218:
204:
200:
190:
188:
184:
180:
179:
175:
170:
125:
105:
85:
23:
22:
15:
12:
11:
5:
267:
265:
257:
256:
251:
241:
240:
235:
234:
216:
198:
172:
171:
169:
166:
127:
126:
124:
123:
115:
113:
107:
106:
104:
103:
95:
93:
87:
86:
84:
83:
75:
73:
67:
66:
62:
61:
58:
54:
53:
49:
48:
45:
39:
38:
24:
14:
13:
10:
9:
6:
4:
3:
2:
266:
255:
252:
250:
247:
246:
244:
232:
228:
227:
220:
217:
214:
210:
209:
202:
199:
183:
177:
174:
167:
165:
163:
162:spartalizumab
158:
156:
153:
149:
145:
141:
137:
133:
121:
117:
116:
114:
112:
108:
101:
97:
96:
94:
92:
88:
81:
77:
76:
74:
72:
68:
63:
59:
55:
52:Clinical data
50:
46:
44:
40:
37:
33:
19:
224:
219:
206:
201:
189:. Retrieved
176:
159:
135:
131:
130:
80:2137049-37-5
226:NCT03484923
208:NCT02460224
132:Ieramilimab
65:Identifiers
57:Other names
29:Ieramilimab
243:Categories
187:. Novartis
168:References
100:OI8P0SFD4R
71:CAS Number
144:developed
148:Novartis
138:) is a
191:9 July
142:being
136:LAG525
120:D12156
60:LAG525
18:LAG525
185:(PDF)
155:LAG-3
193:2015
111:KEGG
91:UNII
43:Type
146:by
245::
195:.
47:?
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.